Abstract:Adoptive cell therapy using chimeric antigen receptor (CAR) technology has become mainstream by employing advanced engineering platforms to promote cancer immunotherapy. CAR T cells have shown remarkable efficacy in the treatment of hematological malignancies; however, the value of this therapy remains inconclusive in the context of solid tumors. Immunotherapy of solid tumors is restrained by several obstacles including the presence of an immunosuppressive tumor microenvironment (TME), limited tumor trafficking, inhibited immune cell infiltration, absence of tumor-specific antigens, and off-target toxicity and adverse events associated with these therapies. Despite recent advances in CAR T cell construction, including the integration of co-stimulatory domains and the creation of armed CAR T cells, with promising outcomes in the treatment of some solid tumors, there are still many unresolved obstacles that need to be overcome. To surmount these impediments to effective CAR T cell therapies, other immune cells, such as natural killer cells and macrophages, have been engineered to serve as appealing alternatives for successful cancer immunotherapy of solid tumors. CAR NK cells demonstrate significant clinical advantages due to their ready availability and minimal toxicity. CAR macrophage (M) cells provide considerable therapeutic potential due to their ability to penetrate the TME of solid tumors. In this review, we comprehensively examine the latest developments and prospects of engineered immune cell-based cancer immunotherapies specifically designed for treating solid tumors. In addition, we provide a concise overview of current clinical trials that are examining the safety and effectiveness of modified immune cells, such as CAR T, CAR NK, and CAR M, in their ability to specifically target solid tumors and promote improved therapeutic outcomes in patients with diverse solid cancers.

Key problems and countermeasures of the immunotherapy for solid tumors

CAR-T in solid tumors: Blazing a new trail through the brambles

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Assessing the Future of Solid Tumor Immunotherapy

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Recent advances and progress in immunotherapy of solid cancers

TCR-T Immunotherapy: The Challenges and Solutions

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Bright future or blind alley? CAR-T cell therapy for solid tumors

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

The Brief Introduction Of CAR-T Cell Therapy in Cancer Tumors

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

CAR T cell therapy: Current limitations and advancements in treating solid tumors

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

A brand new era of cancer immunotherapy: breakthroughs and challenges